AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Artiva Biotherapeutics

Status and phase: Active, not recruiting; Phase 1

Conditions: Refractory Systemic Lupus Erythematosus; SLE; Lupus Nephritis - WHO Class IV; Lupus Nephritis - WHO Class III

Treatments: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: AB-101; Drug: Rituximab; Drug: Obinutuzumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT06265220

AB-101-03

Details and patient eligibility

About

AB-101 (also known as AlloNK) is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that is known to enhance the effect of monoclonal antibody therapies.

This clinical trial will enroll adult patients with lupus nephritis Class III or IV either with or without the presence of Class V who relapsed or did not respond to previous standard of care treatment approaches, or other forms of refractory systemic lupus erythematosus.

The primary objective is to assess the safety, tolerability and preliminary activity of AB-101 plus a B-cell depleting mAb (e.g., rituximab, obinutuzumab) after cyclophosphamide and fludarabine in adult subjects with relapsed/refractory lupus nephritis Class III or IV, with or without the presence of Class V, or other forms of refractory systemic lupus erythematosus.

Patients will be assigned to receive either AB-101 alone as monotherapy or in combination with a B-cell depleting mAb (e.g., rituximab, obinutuzumab). All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and response status.

Patients may receive up to 2 cycles of treatment spaced 24 weeks apart.

Enrollment: 51 estimated patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for all subjects (Lupus Nephritis or SLE)

• Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) Classification Criteria
• Subjects must have had an inadequate response with at least two prior lines of standard of care (SoC) treatment.

Inclusion Criteria for LN:

• Adult subjects with lupus nephritis Class III or IV (with or without the presence of Class V)
• Evidence of active disease on renal biopsy.
• All subjects are required to receive adequate concomitant antihypertensive and antiproteinuric therapy with blockade of the renin-angiotensin system

Inclusion Criteria for SLE:

• Total systemic lupus erythematosus disease activity index (SLEDAI-2K score) ≥ 8, and clinical SLEDAI-2K ≥ 4.
• British Isles Lupus Assessment Group 2004 (BILAG-2004) activity score of A in ≥ 1 organ, or a BILAG-2004 activity score of B in ≥ 2 organs.
• Subjects have failed at least two conventional therapies

Exclusion Criteria:

• Known past or current malignancy
• Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE
• Subjects with known active viral infections
• Severe active CNS Lupus

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

51 participants in 3 patient groups

Phase 1: Dose confirmation of AB-101 as Monotherapy

Experimental group

Treatment:

Drug: AB-101

Drug: Fludarabine

Drug: Cyclophosphamide

Phase 1: Dose confirmation of AB-101 plus Obinutuzumab combination

Experimental group

Treatment:

Drug: Obinutuzumab

Drug: AB-101

Drug: Fludarabine

Drug: Cyclophosphamide

Phase 1: Dose confirmation of AB-101 plus Rituximab combination

Experimental group

Treatment:

Drug: Rituximab

Drug: AB-101

Drug: Fludarabine

Drug: Cyclophosphamide